Samuel J. Reich
CEO · SAB Biotherapeutics, Inc.
Individual
- 2025
- Feb 5, 2026
- 2
Other insiders active in the same sector
No other insider has filed at Samuel J. Reich's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Jesse J. Geiger - $41.11M in MEDP purchases and sales in the last 12 months
- Mark Hancock - $40.97M in PACS purchases and sales in the last 12 months
- Hellman & Friedman Capital Partners X (Parallel), L.P. - $2.65B in MDLN purchases and sales in the last 12 months
- BX Mozart ML-2 Holdco L.P. - $2.35B in MDLN purchases and sales in the last 12 months
- BCP 8 Holdings Mozart Manager L.L.C. - $2.35B in MDLN purchases and sales in the last 12 months
- LILLY ENDOWMENT INC - $2.23B in LLY purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Samuel J. Reich?
Samuel J. Reich is a corporate insider, tracked as CEO of SAB Biotherapeutics, Inc. (SABS). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Samuel J. Reich last file a Form 4?
The most recent primary Form 4 on record is dated 5 February 2026, one of 2 filings going back to 2025.